Novartis AG might soon be able to reclaim some of the kudos it once received for developing groundbreaking transplant-enabling therapies like ciclosporin, through its pioneering of a new class of potential products now in early clinical development.
The Basel, Switzerland-based multinational has an impressive heritage in the organ transplant sector going back more than 30 years, but the company has been rather quiet in this therapeutic arena...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?